Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
Angelini Pharma
|
| gptkbp:acquisitionYear |
2021
|
| gptkbp:focus |
central nervous system disorders
|
| gptkbp:founded |
2019
|
| gptkbp:headquartersLocation |
gptkb:Switzerland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Arvelle Therapeutics
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:product |
gptkb:cenobamate
|
| gptkbp:regionServed |
gptkb:Europe
|
| gptkbp:website |
https://arvelletx.com/
|
| gptkbp:bfsParent |
gptkb:Novo_Holdings
|
| gptkbp:bfsLayer |
7
|